Salute e Benessere
AMI Pharm Advances AYP-101 to Phase 3, Redefining Fat-Reduction Injectable drug with Patient Comfort in Focus
Currently, the only FDA-approved injectable drug for localized fat reduction is based on , which destroys fat cells through . While clinically effective, this cytolytic process causes strong inflammation, often resulting in pain, swelling.
In contrast, AYP-101 selectively induces , a natural and controlled form of programmed cell death that occurs without triggering inflammation. This "silent" process is intended to reduce fat gently, providing a experience for patients seeking non-surgical fat reduction.
AYP-101 is now being tested in a in
South Korea , scheduled for completion by . This follows promising
, which met all primary . In Phase 2, over
of patients achieved at least a on the in the
, with what the company described as .
"AYP-101 is the result of two decades of dedicated R&D," said , CEO of AMI Pharm. "It's the world's first non-cytolytic injectable drug for localized fat reduction, and we believe it will lead the next wave of innovation in aesthetic medicine."
AMI Pharm has presented AYP-101 at global conferences such as and , and is pursuing for global expansion. The company also plans to broaden its clinical focus to include , , and , reinforcing its long-term commitment to innovation.
Logo - https://mma.prnewswire.com/media/2744184/AMI_Pharm_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ami-pharm-advances-ayp-101-to-phase-3-redefining-fat-reduction-injectable-drug-with-patient-comfort-in-focus-302522991.html